Hydromer, Inc. Announces Preliminary Financial Results for Q2 2025
Hydromer, Inc. reports a 14% revenue increase in Q2 2025 despite a net loss, highlighting strategic investments for future growth in the medical device sector.
Hydromer, Inc. (OTC: HYDI), a pioneer in coating technologies for medical devices, has disclosed its preliminary, unaudited financial outcomes for the quarter ending June 30, 2025. The company witnessed a revenue uptick to $0.94 million, marking a 14% rise from the $0.82 million recorded in the same quarter the previous year. However, a net loss of $38,000 was reported, attributed to legal and professional fees alongside costs related to facility and equipment enhancements.
Michael E. Torti, CEO of Hydromer, emphasized the quarter's results as a testament to the company's robust customer relationships and the pivotal role of its coating technologies in the medical device industry. Despite the incurred expenses affecting profitability, Torti views these as essential investments aimed at fostering innovation, expanding market reach, and enhancing financial performance in the forthcoming periods. The company's strategy is centered on advancing its product pipeline, establishing new partnerships, and maintaining operational discipline.
Hydromer's commitment to innovation and scalability is unwavering, with a continued focus on operational efficiency, strengthening customer collaborations, and the development of next-generation technologies. For more information on Hydromer's technologies and services, visit https://www.hydromer.com.
The press release also includes forward-looking statements, cautioning readers about the inherent uncertainties and risks that could influence future outcomes. Hydromer advises against undue reliance on these projections, noting that actual results may vary due to various factors. The company reserves the right to update these statements as necessary, in compliance with legal requirements.